Investor · 1 deal
Every published round Bain Capital Life Sciences took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Participant | Forbes Australia (3 Sep 2026), Forbes Australia (16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio |
Companies Bain Capital Life Sciences has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | Produces radiopharmaceuticals that target cancer cells without the typical collateral dam… | 15 Jul 2026, Series D+ | 1 | 0 |
Fund closes reported for Bain Capital Life Sciences, as distinct from the investments it has made.
Companies Bain Capital Life Sciences has backed that another company then bought. An exit for the holding, not a deal Bain Capital Life Sciences did.
Stories naming Bain Capital Life Sciences. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.